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Mapping Modifiers of protein aggregation 
Anna Lysenko 
June 2014 
Abstract 
 
Polyglutamine expansions that go beyond 35 CAG repeats in disease causing genes such as 
the Huntington gene, cause misfolding of proteins and can lead to aggregation and disease. 
Disruption of proteostasis and aggregation it thought to play a significant role in 
conformational diseases. In addition, there are other aspects that influence onset, progression 
and severity of disease. In this study, we look at how natural variants can contribute to 
increased protein aggregation as well as suppress aggregation. Specifically, we try to map a 
single recessive locus that contributes to increased aggregation in head muscle cells in 
Caenorhabditis elegans, as well as a network of modifiers contributing to suppression of 
aggregation. Here we describe how these strains were created, the process of determining 
whether these phenotypes are a result of a single modifier, or network of genes as well as 
mapping the modifier responsible to high aggregation of head muscle cells. 
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Protein folding and Proteostasis 
 
Protein folding is an essential function in any living organism. Found in the 
coding regions of genes, amino acid sequences define the protein structure. When amino 
acids come together they form a long unfolded chain, which then needs to be folded 
correctly into its tertiary structure to become a functional protein. In the process of 
forming a tertiary structure, proteins go through a process called folding intermediates 
(Gianni et al.,2007). This is a critical point for a protein, and one where the process can 
go awry (Horwich et al.,2002).Proteostasis, or protein-folding homeostasis is when there 
is harmonious function between the biological pathways that control protein synthesis, 
folding, trafficking and degradation.. Disruption in proteostasis is thought to contribute to 
the development of disease; proteostasis disruption can results in off pathway 
intermediates and the formation of toxic oligomers; these are structures made of 
monomers created by aberrant or mutant proteins that can cause aggregation or toxicity to 
occur (Winner et al, 2011, Wetzel et al.,1994) Protein quality control mechanisms, such 
as the ubiquitin-proteasome system (UPS), Unfolded protein response (UPR), 
Endoplasmic Reticulum-associated degradation (ERAD), aggregate clearance via 
autophagy, Heat shock response (HSR) and chaperone systems are critical in maintaining 
stability of protein folding. These are essential cellular functions, and without molecular 
chaperone assistance or proper degradation (Roth et al.,2008), aberrant proteins are more 
prone to misfolding (Bence et al.,2001, Bukau et al.,2006).  
Two mechanisms that are used to alleviate the stress of misfolded proteins and 
attempt to prevent aggregation, are folding the proteins with the assistance of molecular 
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chaperones (Hartl, et al.2011, Bar-Lavan et al.,2012) or if this is not possible, target the 
misfolded proteins for degradation (Powers et al.,2009). Misfolded proteins that are not 
refolded to their native state, or have been targeted for degradation prematurely and 
remain functional but abarrent, are a contributing factor in conformational 
neurodegenerative diseases. Protein quality control is an essential process, that if 
disrupted can have detrimental effects  
 
Molecular chaperone 
 
Molecular chaperones, such as Hsp70, are able to convert toxic aggregates and 
misfolded proteins to their native forms (Hinault et al.,2010, Bukau et al.,2006) In an 
ideal situation, molecular chaperones would assist in  folding proteins to  their proper 
form. In situations where there is an overproduction of mutant protein, such as a mutant 
huntingtin , molecular chaperones attempt to refold them, and failure in these 
mechanisms may in part be responsible for disease. Organisms can delay disease onset 
and show the ability to protect against aggregation by increasing chaperone activity 
through gene overexpression such as hsf-1 which a transcription  factor activated in a 
cellular stress response, suggesting chaperones have to ability to mediate aggregation 
(Morley et al., 2004, Cohen et al.,2006).  Molecular chaperones are also critical in 
tagging mutant proteins for degradation, and proper disposal can prevent disease causing 
aggregates. Failure of these mechanisms may be the cause or a contributing factor in 
neurodegenerative diseases (Bennett et al.,2002, Bukau et al.,2006).  Stable oligomers 
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have been shown to hinder chaperone activity, leading to buildup of these mutant protein 
oligomers, and as a result disease causing aggregation (Hinault et al.,2010).  
 
Polyglutamine 
 
 Conformational neurodegenerative diseases such as Parkinson’s, Alzheimer’s, 
Amyotrophic Lateral Sclerosis and Huntington’s disease, are diseases associated with 
buildup of plaques and aggregates (Kakizuk et al.,1998, Chen et al.,2002).  For example 
Huntington’s disease is caused by polyglutamine (polyQ) expansions (Kopito and Ron, 
2000), or CAG repeats, that results in detrimental muscular, neurological and cognitive 
effects (Orr, 2001). Polyglutamine expansions are long stretches of CAG repeats that 
code for the amino acid Glutamine.  Studies performed on brain tissue of postmortem 
patients displaying symptoms of Huntington’s disease, have identified aggregation of 
mutated huntingtin protein (Kakizuka et al.,1998, Chen et al.,2002). A number of GWAS 
and cohort studies performed, such as a study done on Venezuelan kindreds, reveals 
strong correlations between length of CAG repeat in an individual and their age of onset 
and severity of disease (Wexler et al.,2004, Brinkman et al.,1997).In many cases, we still 
do not understand the mechanisms that cause the aggregation of misfolded proteins, and 
why they are toxic, which contributes to our inability to find effective treatments.   
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Conformational neurodegenerative disease 
  
Huntington’s disease, as well as other trinucleotide repeat disorders and 
conformational neurodegenerative diseases, such as X-linked spinal and bulbar muscular 
atrophy, fragile X syndromes, and spinocerebellar ataxia (La Spara et al.,1994), are 
caused by a gain-of-function mutation that results in unstable proteins.. These mutated 
proteins can result in a disruption of the global balance of protein folding, and not only 
influence aggregation of one mutant protein, but result in misfolding of other proteins 
necessary for cellular function; this imbalance results in quicker aggregation of disease 
proteins such an huntingtin  (Gidalevitz et.al.,2006,). Hindering chaperone activity 
(Hunault et al.,2010) as well as the activity of other proteins required for cellular function 
(Olzscha et al.,2011), these misfolded proteins lead to a dysfunction of protein folding 
and degradation pathways; as an example, studies have been done that show aggregation 
of human amyloidogenic proteins interfere with proteostasis in numerous models such as 
C.elegans, (Gidalevitz et al.,2006), and yeast (Eremenko et al.,2012) . Polyglutamine 
expansions, beyond the acceptable threshold of 35 CAG repeats, lead to the 
conformational changes in protein and result in misfolded protein, and ultimately 
aggregation (Stine et al.,1993, Soto CJ.,2003, Dobson et al.,2003, Kakizuka, 1998) 
(figure 1 and 2). 
 CAG repeats can vary from 6 to 39 repeats in an individual unaffected by the disease, 
and can range from 36 to 180 repeats in an individual showing symptoms of Huntington’s 
(Rubunsztein et al.,1996, Satbasivam et al.,1997). The threshold for the disease is very 
abrupt, a person without Huntington’s  can have  34 repeats present, while one with the 
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disease can have 36 (Duyao et al, 1993).  Persons with repeats slightly above the disease 
threshold tend to show disease symptoms in old age, beyond their 50’s, while juvenile 
onset Huntington’s is seen in patients with 50 and higher repeats (Brinkman et al.,1997). 
Age and CAG repeat length are two major contributing factors in diseases such as 
Huntington’s. The aggregation of misfolded proteins and subsequent increase in toxicity 
is intensified as an individual with one of these diseases ages, but this is also tied to the 
number of CAG repeats (Morley et al., 2002, Brinckman et al.,1997). The efficiency of 
proteostasis declines with age either due to environmental stressors or intrinsic variation 
resulting from polymorphisms and disease causing mutations (Kikis et al.,2012). Using 
C.elegans as a model, it has been shown that there are several hundred proteins that 
become insoluble as the organism ages, suggesting protein folding mechanisms might 
decline in function and can have detrimental disease consequences (David et al.,2010  
It has been shown that there are early misfolded proteins present prior to the 
appearance of disease symptoms. It is now possible to detect trace amounts of misfolded 
proteins in early age mice, whereas large inclusion bodies are not found until much later 
in life (Gupta et al.,2011) This early misfolding and aggregation formed by an array of 
proteins other than the disease associated protein, such as HypF protein in E.coli and 
P13-SH3 from bovine, both which are small globular proteins that are capable of forming 
fibrillar aggregates in vitro but are non pathogenic (Bucciantini et al., 2002) These 
aggregates have been shown to be cytotoxic and causes cellular dysfunction that leads to 
quicker aggregation and buildup of plaques of pathogenic mutant proteins(Bucciantini et 
al.,2002) This demonstrates that avoiding aggregation of any protein is crucial in 
preserving proper biological and cellular functions.  
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Natural variation and disease 
 
Natural variation in genetic background that occur due to random mutations can 
assist or prevent organisms from successfully adapting to unfavorable internal conditions, 
such as aberrant proteins  (Gidalevitz et al.,2013). It is well know that genetic variation in 
individuals genetic background influence phenotypic expression of conformational 
disease (Genin et al.,2008, Doetschamn et al.,2009). Conformational diseases tend to 
have a large variability in the age of onset (Wexler et al.,2004). Even though mutations 
that are causative of these diseases are expressed from birth, onset is typically seen later 
in life. In the example of Huntington’s diseases, the length of polyglutamine repeats will 
be in part the determining factor of the age of onset of the disease (figure 3)(Wexler et 
al.,2003), In individuals with 40 to 50 CAG repeats, polyQ length accounts for about 
44% of  variation in the age of onset as well as the severity of the disease, while in 
individuals with greater than 50 CAG repeats, it accounts for 72% of the variation. Of the 
residual variation, the remaining difference in age of onset and severity of disease , about 
40% is attributed to genes other than the Huntington gene, while 60% is attributed to 
environmental factors (Wexler et al.2003). This variation in onset of the disease even in 
individuals with the same number of polyQ repeats, is indicative of other natural variants 
that may be present and influencing the disease progression. This brings us to the 
question of what are the other genetic modifiers cause this variation in disease onset and 
severity, in patients with the same length of polyQ expansions. 
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Natural genetic variation determines susceptibility to mutation-induced protein 
aggregation (Gidalevitz et al., 2013). It is as important to study natural variants present in 
an individual’s background as important as it is to study disease genes themselves. 
Although genetic manipulations such as knockout/knock-in organisms have provided a 
wealth of information on stress response pathways and adaptation mechanisms, these 
gene modifications that are not naturally produced can have adverse effects on an 
organism and its development and fitness(Jenkins et.al.,2004).   Looking at how natural 
variants affect disease phenotype allows us to use modifiers to our advantage that are 
compatible with normal development of an organism (Hamilton et.al.,2012).  Natural 
variants in genetic background can dampen or enhance the aggregation of mutant 
proteins, by enhancing or suppressing pathways involved in the process. Using a model 
organism such as C.elegans allows us to identify these pathways and provides a valuable 
tool for understanding how variants in genetic background influence disease outcome 
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 Figure 1: Protein folding. When protein homeostasis is maintained, proteins go from a nacent 
polypeptide, to a folding intermediate and finally a native protein. Different factors can contribute to 
disruption of this process, such as environmental stressors, mutations or translational errors. This can 
lead to misfolded proteins. In ideal circumstances, proteins will either be assisted by chaperones and 
refolded to their correct state, or degraded. In some situations, proteins can stay misfolded, and in turn 
form aggregates. This can lead to disease.  
(Adapted from Gidalevtiz et al., 2013) 
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Figure 2: Types of aggregates formed in conformational diseases. Protein 
aggregation can lead to diseases such as Alzheimer’s, Parkinson’s, 
Huntington’s, Prion and Amyotrophic later sclerosis. Although each 
disease has its own associated protein that misfolds and aggregates, the 
structures of the plaques and aggregates is the same between diseases. 
These diseases vary highly in their age of onset and severity. They can be 
sporadic or inherited. (Adapted from Soto CJ, 2003) 
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Figure 3:Variation in Huntington’s disease. Conformational diseases such 
Huntington’s disease, which is shown here, display high variability in 
their age of onset, severity and progression. In part this is due to the 
length of polyglutamine repeats. There are also other factors that are 
involved in this variability, including other natural genetics variations 
found in different patients. These naturally occurring genetic variations 
contribute to the variability in onset shown here, even in patients with the 
same number of CAG repeats. (Adapted from Wexler et al.,2004) 
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Caenorhabditis elegans as a model organism 
 
When studying conformational diseases and the influence natural variants in genetic 
background have on its outcome, it is important to choose a model organism that will allow 
us to study multiple aspects of the disease. This includes aggregation of proteins, toxicity that 
is caused by protein aggregation, longevity, and motor abilities, all of which are symptoms 
associated with protein conformational diseases.  C.elegans is a very effective model 
organism for studying conformational diseases (figure 4). Their short generation time, which 
is approximately 3.5 days, makes it easy to create recombinant inbred lines, allowing you to 
study effects of recombination and different genetic background on disease. Short life span, 
with a maximum survival of 30 days, makes the study of lifespan in this system easier than in 
other systems, such as rodents (Wormbase). The ability to cultivate C. elegans in very large 
colonies allows for easy development of experiments that have statistical significance. 
Important to the study of protein aggregation, the transparent body wall of C. elegans allows 
for the observation of protein aggregation with simple microscopy techniques in live 
organism’s using GFP-fusion protein to visualize the aggregation process (Markaki and 
Tavernarakis, 2010), while some other models used for the study of Huntington’s disease 
such as mice and rats, necessitate euthanization to study protein aggregation.   
C.elegans are also a valuable tool due to their high genetic variation in different 
strains found in different parts of the world, as an example Hawaiian genetic distance to 
N2 being 1.2-2.7 10
-3 
per nucleotide (figure 5). This allows for the creation of genetically 
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diverse populations, which are key in studying natural variation in genetic backgrounds, 
and how they affect disease.  The C. elegans genome has been completely sequenced, 
and in addition to their genetic diversity, this provides a valuable tool for studying 
mechanisms that control polyglutamine aggregation Due to this genetic diversity, it is 
possible to study how natural variants in genetic background contribute to the outcome of 
disease; and C.elegans can be used as a tool to study these natural variants, and their 
influence on mutant proteins and disease.  
The model used to study the influence of natural variants in genetic background 
have on disease is a Bristol laboratory strain with a 40 polyglutamine expansion. The 40 
polyQ expansion was fused to YFP for visualization, with a myosin heavy chain 
promoter and integrated into a location on the X chromosome. This model has Q40 
expressed in the muscle cells.  
C.elegans display a threshold for polyQ repeats, much like humans do (figure 6). 
It has been previously shown that genetic variation among wild isolates of C. elegans 
influences aggregation of polyQ (Gidalevitz et al, 2013) (figure 7).  
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: C.elegans.C.elegans are a valuable tool in studying conformation 
diseases. Their small size and fast generation time makes it easy to study 
genetic variation influences on disease as well as perform numerous replicates. 
They are also transparent, which allows for the study of protein aggregation 
diseases in real time, without euthanization of the animal. 
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Figure 5: C.elegans wild isolates. Different wild isolates of 
C.elegans found in different parts of the world display significant 
variance in their genetic backgrounds. (Adapted from 
Wormbook). 
15 
 
 
 
Recombinant inbred lines in the study of natural variation in disease 
 
A panel of 21 recombinant inbred lines (RILs)- which are organisms from the 
same parental strains, but through independent recombination followed by self 
reproduction, result in a panel of strains with different recombinant genetic backgrounds- 
were created by random selection of random F2 progeny from a cross of a wild isolate 
DR1350 and a laboratory strain Q40Bristol, also displayed a large variation in polyQ 
aggregation (Gidalevitz et al, 2013)(figure 8 and 9). This shows that genetic background 
has a large influence on the aggregation patterns in organisms containing the same 40 
polyglutamine expansion. Independent recombination events can lead to different genes 
being inherited from either parent, resulting in mixed genetic background, and different 
aggregation phenotypes. Of particular interest to this project came a set of RIL’s that 
display high head aggregation and high body aggregation, as well as a line that had 
complete suppression of aggregation, neither of which is consistent with any parental 
aggregation patterns (figure 9 and 10). RIL 2 was chosen as a representative to study this 
phenomenon of high aggregation in the head muscle cells (figure 9). These two strains, 
one with very high aggregation in head muscle cells and one with very suppressed 
aggregation, indicate that there are natural variants that can occur in genetic background 
that influence disease progression in organisms with the same length of polyglutamine 
repeats.  
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            Natural variation in genetic background plays an important role in the onset and 
severity of disease. It is important to understand how an individual’s genetic makeup can 
influence disease progression. In this study, we look at how genetic background can 
influence protein aggregation and how to determine whether single modifiers or networks 
of genes are responsible. 
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Figure 6: Threshold for polyglutamine aggregation. 
The threshold for polyglutamine aggregation as 
shown here is 40 CAG repeats. Lower than 40 
repeats, we only see soluble protein. (Adapted from 
Morley et al.,2002) 
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: RIL 2 and Q40Bristol. RIL 2 displays high aggregation 
of head muscle cells with early onset, this phenotype is not present 
in its parent Q40 Bristol. (Gidalevitz et al.,2013) 
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Results 
 
Previous work 
Results described in this section are contributed by Jasmine Alexander-Floyd and Gowri 
Gouda 
 
 It was initially important to identify whether the presence of high  polyglutamine 
aggregation in the head muscle cells was caused by genetic variation  at a single locus, or 
by a network of genes. This is important because mapping a single locus can be done 
with mapping strains and SNP mapping, while mapping a network or genes would 
involve different methods to determine how multiple genes work together to produce one 
phenotype.  In the initial panel of recombinant inbred lines, 5 out of 20 RIL;s displayed 
high aggregation in head muscle cells; since all of these were a result of independent 
recombination events, and the expectation would be that different recombination events 
would lead to differing phenotypes, it was suggestive of a single recessive locus being 
responsible for the high aggregation in head muscle cells. To confirm this initial 
observation, RIL 2 was backcrossed to its parental strain, Q40 Bristol, and by looking at 
patterns of inheritance, we could see a 3:1 inheritance ratio in F2 progeny; where 75% 
showed  Q40Bristol like phenotypes (1,629), and 25% showed high aggregation in the 
head muscle cells (528) (Jasmine Alexander-Floyd, unpublished observations) (figure 
11). This again indicated the presence of a single recessive locus responsible for the early 
onset of aggregation in head muscle cells. 
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Next the location of this locus was mapped to roughly the center of chromosome I 
using mapping strains. This was done by using a strain with a single marker on each 
chromosome to identify what chromosome the modifier lies on and roughly where on the 
chromosome. Then, using two point mapping by crossing RIL 2 to a double mutant 
mapping strain with phenotypic markers in different areas of chromosome I, it was 
attempted to map the modifier further. Markers unc-11, at 3798566bp, and dpy-5, at 
5432158bp, were used for the left are and markers dpy-5, at 5432158bp, and unc-13, at 
7422785bp, were used for the right arm of the chromosome. The distribution of 
phenotypes was scored in F2 progeny after crossing RIL 2 into one of these strains. F1’s 
were selected and then the F2 progeny were scored for unc non-dpy and dpy non-unc 
phenotypes. These phenotypes were scored because they occur based on recombination 
events that would help determine if the modifier was in between the two markers. 
Inconsistent results suggested there were genetic factors in this region affecting 
recombination frequencies. This could be explained, for example, by the presence of 
small deletions or duplications in the genomes of the parental strains.  Some results were 
suggestive of it possibly lying toward the left side of the chromosome, but because this 
was not consistent, the strain was sent for sequencing.  
Prior to sequencing, to isolate the locus that contributes to head muscle cell 
aggregation, and filter out variants that do not contribute to this phenotype, RIL 2 was 
backcrossed to its parental strain Bristol 23 times. This was done with selection for the 
head muscle cell aggregation phenotype at each F2 generation, using the following 
crossing scheme: RIL 2 hermaphrodites were set up to mate with Q40 Bristol males; 
because we have previously determined that RIL2 phenotype was recessive, F1 cross 
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progeny was identified by having a Q40Bristol like phenotype. F2 progeny were selected 
based on the RIL2-like phenotype - high aggregation in the head muscle cells. This was 
repeated 23 times. The goal was to isolate as small of a donor fragment containing 
causative variants, in a predominantly wild type Bristol background (figure 12) 
(Gidalevitz et al.,2013). RIL 2 (23 times backcrossed) was sequenced using whole 
genome high throughput sequencing at the Wistar institute. After sequencing, a 1.5Mb 
region of interest between 832kb and 2.22Mb on the left arm of chromosome I was 
identified using Cloudmap through Galaxy (Minevich et al.,2012). This region was found 
to contain high density of DR1350-derived SNPs (approximately 300 changes/100kb) 
(figure 13), and was located on the left arm of chromosome I. Since this location was 
consistent with the three-point mapping results, it was chosen as a candidate locus. A list 
of potential genes found in this area was created by choosing SNPs that are in regulatory 
regions and thus could control the expression of genes, as well as non-synonymous SNPs, 
resulting in approximately 100 genes. Some genes are of particular interest such as moag-
4, which specifically modifies amyloid aggregation, including in Q40 C. elegans model, 
by interaction with early amyloid precursor (TJ van Ham - 2010 Cell  Falsone et 
al.,2012). A few others of particular interest in this region are SHC1 (Src Homology 2 
Domain Containing transforming protein 1) that is important for regulation  of apoptosis, 
and interacts with the insulin-like signaling pathway to influence stress response and 
longevity; it encodes three isoforms, one of which may be involved in lifespan regulation 
and stress response to reactive oxygen species, while the other two act on the Ras 
pathway, which activates genes responsible for cell growth, differentiation and survival. 
atg-5 (Autophagy related 5) is another gene of importance and plays a role in building 
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autophagosomes, necessary for autophagy and aberrant protein disposal; ubc-3 encodes 
for an E2 ubiquitin ligase  (homologue of yeast and human CDC34) and is also important 
in protein degradation and ubiquitination.  
After the region of interest was identified, further backcrossing was performed to 
attempt to decrease the size of the donor fragment. During this backcrossing, a series of 
lines were isolated based on differing phenotypes. These were given their own names and 
used as independent lines for further mapping (figure 14). This was important because 
different phenotypes that were rare, could indicate rare recombination events that could 
possibly have occurred in the donor fragment during backcrossing. These strains could 
potentially play valuable roles in shortening the donor fragment and decreasing the list of 
potential genes contributing to the high aggregation in the head muscle cells. Among 
those isolated out were two strains that were smaller, less reproductive and had much 
higher body aggregation. These were named 8a and 8b. 8a maintained the high head 
aggregation phenotype, but was more highly aggregated than the original RIL 2, while 8b 
lost the high head aggregation phenotype, but maintained the high body aggregation. This 
was of great value because any overlap in the donor fragment found in 8b and other 
RIL’s could be eliminated from the gene list. This is because 8b was isolated from RIL 2, 
but lost its early onset of aggregation in the head muscle cells, in turn losing the modifier 
responsible for this phenotype. Line #7 is RIL 2 continuously backcrossed and currently 
on backcross 33. Line #9 was isolated out for being slightly more aggregated, and slightly 
smaller than line #7, but still maintaining the phenotype. 
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Current work 
Following identification of this 1.5Mb region, we attempted to narrow down the 
size of the donor fragment by SNP mapping protocol (Davis et al.,2005). It was necessary 
to narrow down the list of potential target genes to be able to take a deeper approach to 
study candidate genes and their effect on the phenotype and pathways they are involved 
in.  
The SNP mapping approach was used to try to find the breakpoints of the donor 
fragment based on data compared from a number of strains. RIL’s 12, 12(2), 15 and 18 
were tested to determine if their donor fragments were smaller in size compared to RIL 2. 
This was done because all these lines display increased head muscle cell aggregation 
pattern, but acquired this phenotype through independent recombination events. In 
addition to RILs, four strains generated during backcrossing were also used – designated 
as lines 7, 8a, 8b, and 9. A combination of data from all of the RIL’s and lines created 
through independent recombination events may allow us to narrow down the size of the 
donor fragment, and narrow down our list of target genes.  
Primers were designed to cover the candidate region between 832kb and 2.22Mb 
on the left arm of chromosome I.  We selected 8 primer pairs, each designed to amplify a 
small region containing a SNP within the donor fragment that would indicate what 
background is present in this location, either DR1350 or Bristol (figure 15). RIL 2 (23x 
backcrossed) and Q40 Bristol were used to test these primers and optimize PCR and 
restriction digest conditions. For example, primer pair 1 was designed to amplify 
genomic fragment from 832228bp to 832907bp that contained a SNP at position 832671. 
This SNP results in a loss of the recognition site for ApoI restriction nuclease in DR1350 
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background; a resulting PCR fragment will be susceptible to the digest with ApoI if 
amplified from Bristol background, and resistant if amplified from DR1350 background 
(figure 16). Genotyping performed using primer pair 1 revealed that all lines - RIL’s 12, 
12(2), 15 and 18 as well as lines 7, 8a and 8b, have a DR1350 background present in this 
location. This can be seen by the generation of bands consistent with the sizes expected 
from the loss of a restriction site - 331bp and 175bp (figure 17). This is also the case for 
primer pair 3, where a loss of a restriction site, resulting in a 603bp band, indicates a 
DR1350 background present in this position (figure 18). This shows that none of the 
RIL’s or the strains isolated during backcrossing have a shorter donor fragment 5’ side of 
the donor fragment since all show genotyping results consistent with DR1350 genetic 
background.  
Genotyping performed using primer pair 8 revealed digested PCR products at 
around 278bp and 206bp (figure 19), consistent with DR1350 background, for all lines 
tested except RIL 15 and line 7. RIL 15 and line 7 appeared to have a Bristol background 
at this position (figure 19, lanes 7 and 11, respectively), since there is a loss of a 
restriction site in the Bristol background, resulting in no digest of the PCR product. This 
was an important result because it indicated further genotyping should only be performed 
on RIL 15 and line 7. It also helped conclude that although all RILs were the result of 
independent recombination, they inherited atleast the same size donor fragment as RIL 
2,indicating the importance of the genes within this region.  
Since the interpretation that RIL 15 and line 7 have shorter donor fragments is 
based on the lack of restriction digest, it was treated as a suggestive result, because if 
conditions are not optimal, a failure of digest can occur and give a false result in this 
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situation. Therefore, primer pair 7 was designed, 240 Kb 5’ to the primer pair 8 location. 
This would not only confirm the result, but it would also show whether the region is even 
smaller, allowing us to narrow down the list of possible gene targets further. After this 
genotyping, it was evident that RIL 15, line 8b, and line 7,all had a shorter donor 
fragments (figure 20, lanes 7, 8, and 11, respectively).  This was based on the digest of 
the PCR product and products around 227bp and 145bp, consistent with Bristol 
background. 
To map the 5’ boundary between the DR1350 and Bristol backgrounds in the 
lines with the shorter donor fragment, the RIL’s and line #7 were tested for primer pair 5, 
which is roughly in the center of the donor fragment. This genotyping showed no digest 
of the 743bp PCR products, indicating that all RIL’s have a DR1350 background present 
in this location (figure 21). This suggests that the breakpoint of the donor fragment is 
somewhere between the locations of primer pairs 5 and 7.  
 After this result, a new primer pair was designed that falls roughly in between 
primer pairs 5 and 7, at 1.81Mb. This primer pair was used to test RIL 15 and line 7, 
because they have been shown to have shorter donor fragments, as well as line 8b to 
determine if there was any overlap. The results indicate both the lines have a DR1350 
background in this location, now putting our donor fragment breakpoint between 1.81Mb 
and 1.98Mb. (Figure 22). For line 8b, the results indicated that there was Bristol 
background in this location, resulting in an even shorter donor fragment line. These 
results eliminated approximately 20 genes from the 3’ side of the donor fragment, After 
determining where the breakpoint of the donor fragment is for line 8b, this will allow us 
to cut out even more genes. Ideally the breakpoint will fall between closer to 1.64Mb 
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primer, with a large overlap between RIL 15, line 7 and line 8b. If the breakpoint falls 
closer to the primer pair at 1.17Mb, this will result in a smaller overlap, with a larger 
number of genes to test further. 
  
Is suppression of aggregation a result of a single modifier or a network of genes? 
 
An interesting question is whether similar modifiers and mechanisms are used in 
suppressing aggregation, as in causing high aggregation. To look at this, in addition to 
mapping the single recessive locus responsible for high aggregation in head muscle cells, 
we took a brief look at the suppression of aggregation in RIL’s and focused on RIL 16 
(Figure 9) to determine whether it was controlled by a single recessive locus as well, or if 
there were more players. RIL 16 has suppression of aggregation and has the lowest 
aggregation of all the RIL’s, with approximately 1 aggregate present at late L4 stage, 
while Q40 Bristol will have over 10 (figure 23). It is interesting to look at whether there 
are any similar underlying genes controlling both high aggregation of head muscle cells, 
and suppression of aggregation. These experiments were performed to determine this.  
We first wanted to test whether the suppression of aggregation is a result of a 
single modifier or a network of genes.  RIL 16 was crossed to Q40 Bristol to determine 
how the phenotype is inherited, much like RIL2 was.  In the F1 generation we found 
there was moderate suppression of aggregation, and no progeny showed high aggregation 
like the Q40 Bristol parent. This indicates a dominant inheritance, which was not seen in 
RIL 2. F2 progeny were then singled out and allowed to self reproduce. In the F2 progeny 
we detected large variability in the aggregation phenotypes. There were 7 out of 20 
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progeny in F2 generation that showed RIL 16 like suppression of aggregation, which 
initially indicated a potential recessive locus involved in suppression of aggregation 
(figure 24). But when F2’s were allowed to self reproduce, we saw again a large variation 
in their phenotypes. Suppression of aggregation in F2 was not an indication that there 
would be similar suppression in their self progeny (figure 25). This is suggestive of a 
network of genes involved in regulating suppression of aggregation, and that multiple 
variants need to be inherited in order to see this protective phenotype.  These results 
indicate there probably is not much overlap between the modifiers controlling 
suppression of aggregation and the modifier controlling high aggregation of head muscle 
cells. 
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Figure 11: High aggregation of head muscle cells is controlled by a single 
recessive locus. RIL 2 was crossed back to its parental strain, Q40 Bristol, to 
determine what the inheritance was for the RIL 2 phenotype. F1 progeny that 
were heterozygous were allowed to self-reproduce, F2’s were counted. With the 
resulting number, it is evident we have a 3:1 segregation, much like it was seen 
in the panel of 20 RIL’s. This is suggestive of high aggregation in head muscle 
cells being controlled by a single recessive locus. (Jasmine Alexander-Floyd) 
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Figure 12: Backcrossing RIL 2. RIL 2 was backcrossed 23 times to 
filter out natural variants not contributing to its phenotype and isolate 
the locus responsible for the early onset aggregation in the head 
muscle cells in a predominantly Bristol background.  
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Figure 13: Sequencing results of RIL 2. Through sequencing and 
analysis using Cloudmap in Galaxy, a 1.5Mb region of interest 
was identified on the left arm of chromosome I. This region 
contains ~300 changes/100kb. (Adapted from Jasmine 
Alexander-Floyd) 
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Figure 14: Independent lines isolated during backcrossing RIL2. 
Independent lines were isolated during further backcrossing of RIL 2 
(23xbackcrossed) in an attempt to decrease the size of the donor fragment. 
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Figure 15: Primers spanning the 1.5Mb region of interest in RIL 2. A 
series of primers were designed to span the region of interest in RIL 2 that 
contains the recessive modifier contributing to its phenotype. Each primer 
pair amplifies a region that gains or loses a restriction site, creating a 
different pattern of digest, or complete loss of digest. This allows us to 
determine whether a DR1350 or Bristol background is present in that 
location.  
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Figure 16: An example of the results for genotyping using primer 
pair 1. If crossover happens slightly to the right of primer pair 1 
during backcrossing, you will have the Bristol genotyping result. If 
it does not, you will have a DR1350 genotyping result. 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Genotyping data for primer pair 3. Lanes 1-4 show RILs 12, 
12(2), 15 and 18 undigested PCR products, and lanes 5-8 and 11-12 show 
digested PCR products. A loss of a restriction site, resulting in no digest of 
the PCR product is suggestive of a DR1350 background present in this 
location 
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Figure 19: Genotyping for primer pair 8. Lanes 1-4 and 11-12 show 
undigested PCR products for RILs 12, 12(2), 15 and 18. Lanes 5-8 and 
13-14 show digested PCR products. Of particular interest are lanes 
number 7 and 13, which show no digest of the PCR product. A loss of a 
digest site at this location is suggestive of a Bristol background at this 
location 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Genotyping for primer pair 7. Lanes 1-4 represent 
undigested PCR products for primer pair 7, using Q40 Bristol in lanes 
1 and 2 with different DNA concentrationsRIL 15 in lane 3 and line 
8b in lane 4. Lanes 5-8 represent digested samples in the same order, 
Lane 9 is a no template control. Partial digests can be seen in 3 of the 
samples, where the PCR product was not entirely digested by the 
enzyme. Lanes 10 is undigested PCR product for line #7 and lane 11 
is digested PCR product for line #7,these show line 7 also has a 
Bristol background present in this position 
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Figure 21: Genotyping for primer pair 5. RIL’s 12, 12(2), 15 and 18 were 
genotyped for primer pair 5. Lanes 1-4 show undigested PCR products. Lanes 5-
8 show digested PCR products. Loss of a restriction site indicates a DR1350 
background present in this location for all RILs. 
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Figure 22: Primer pair 1.81 genotyping.  Q40 Bristol, RIL 2, line 7, 8b and 
RIL 15 were genotyped for the new primer pair at position 1.81Mb. Lanes 1-
5 are undigested PCR products of these lines .Lanes 6-10 are digested 
products. Digests in lanes 7,8 and 10 indicate a DR1350 background in these 
positions, while digests in lanes 1 and 4 indicate Bristol background in this 
position.  
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Figure 23: F1 generation in a cross between Q40 Bristol 
and RIL 16 show moderate suppression, with no progeny 
displaying high aggregation phenotype seen in Q40 
Bristol. Q40;PD4792 was a strain used with a neuronal 
marker to help identify cross progeny. 
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Figure 24: F2 progeny from experiment in Figure 23 were 
singled out and scored for aggregation. There is a wide range of 
phenotypes seen from complete suppression to very high 
aggregation. 7 out of 20 nematodes had suppression of 
aggregation similar to that seen in RIL 16. 
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Figure 25: F2 animals from Figure 24 were allowed to self 
reproduce and F3 progeny were scored for aggregation. Data 
are arranged as in Figure 24, from F3 progeny of F2 parents 
with lowest aggregation on the left to those from F2 parents 
with highest aggregation on the right. A wide range of 
phenotypes is seen again, and suppression in F2 is not an 
indication of suppression in F3. This is suggestive of a network 
of genes that need to be inherited together to see suppression of 
aggregation.  
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Summary and future experiments 
 
 
 As a result of SNP mapping and attempting to find the location of the single 
recessive locus that is believed to be responsible for early onset of aggregation in head 
muscle cells, we have narrowed down the region of interest to a smaller donor fragment, 
and cut the list of genes to between 25 and 53 that are of interest, based on determining a 
small region where the breakpoint of the donor fragment lies for RIL15 and line 7, 
between 1.81Mb and 1.98Kb, and where the donor fragment breakpoint for line 8b lies 
between 1.17 Mb and 1.64Mb.  
Currently the lines that are of particular interest are RIL 15 and lines 7 and 8b. 
These are of interest because RIL 15 and line 7 both have shortened donor fragments, but 
maintain the high aggregation of head muscle cells phenotype. While line 8b was a result 
of backcrossing and has lost its high head aggregation, but still has at least part of the 
donor fragment present (figure 26). This allows us to eliminate any genes present in 
overlap with line 8b. Depending where the breakpoint of the donor fragment lies, this 
allows us to cut our list of genes down to between 27 and  55 genes, bringing the list of 
potential genes that to between 53 and 25. This brings us to a much more manageable list 
of genes. Further fine tune mapping by sequencing will be necessary to find the true 
breakpoints of these fragments, and determine what genes are left that are of particular 
interest. After identification of a shorter list of genes, other experiments can be carried 
out to determine which gene in the list is responsible for high aggregation of head muscle 
cells. This can be done through a series of different experiments such as RNAi to 
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downregulate target genes. This would allow us to see if downregulation of a specific 
gene from the narrowed down gene list would cause the high head aggregation phenotype 
in Q40Bristol. By using Q40Bristol in RNAi experiments we would be able to determine 
if certain genes, from our target gene list, with a loss of function are the reason for high 
aggregation in head muscle cells. Alternatively, experiments can be performed using 
cosmid injections into the RIL 2 with DR1350 background to see if it is possible to 
rescue the high aggregation phenotype. These approaches assume that the modifier is not 
part of a larger network of genes within a single locus. If it turns out a single modifier 
does not influence the phenotype on its own, it will be necessary to further test pathways 
it can be involved in, and what other genes are present in this pathway that work together 
to produce this phenotype. 
 Following identification of the modifier, experiments need to be performed to 
determine whether the effects of this modifier are unique to polyQ, or whether it will 
have the same effects on other proteins that cause aggregation in other conformational 
neurodegenerative diseases, such as Amyloid-β in an Alzheimer’s model. Identification 
of this modifier would lead us to a better understanding of how networks of genes present 
in an individual’s background work together to influence the phenotypic outcome of a 
disease. This is valuable information to understand why individuals that have the same 
number of CAG repeats, but different age of onset and severity of disease. 
For RIL 16, now that we are aware of a complex inheritance being responsible for 
the suppression of aggregation, further mapping needs to be performed to determine what 
chromosome/chromosomes these genes lie on, and perform linkage analysis to get further 
in identifying them. This is of great importance because this shows that we can model 
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diseases with complex inheritance in C.elegans. A large number of diseases have a 
complex genetic inheritance or, like in the example of Huntington’s disease, show 
significant influence of the individual’s genetic background, despite in itself being a 
monogenic disease. This is critical in moving research in this area forward and we can 
take this model system beyond identifying single target genes.  Further research using 
this line would allow us to identify methods we can use to map complex inheritance in 
diseases and determine how networks of genes work together to create a disease 
phenotype. 
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Figure 26: Results of donor fragment sizes for all RILs and lines 
isolated during backcrossing. Blue indicates Bristol background; red 
indicated the sizes of the donor fragments. Yellow? indicates regions 
of uncertainty that need to be mapped further to determine exact 
breakpoints for these lines. 
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